Latest Articles & Resources FEATURED Vertex on Building Risk Into Manufacturing Network Strategy Read More » Vertex on Building Risk Into Manufacturing Network Strategy Read More » LATEST NEWS + INTERVIEWS Charles River Laboratories Partners With Medigen on Multivalent Enterovirus Vaccine How to Connect a CDMO Network Without Starting From Scratch Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study of Gemini in Acute Kidney Injury Cytovance Biologics Expands Standalone Analytical Services for Biologics VectorBuilder Partners With Lir Therapeutics to Advance AI-Engineered AAV Capsids SK pharmteco Opens Expanded Swords Facilities for Small Molecules and HPAPIs Andelyn Biosciences Partners With Queen’s University on AAV9-GM2 Gene Therapy Entropy Neurodynamics Partners With BioCina on GMP Psilocin Manufacturing Piramal Pharma Acquires 40.67% Stake in Yapan Bio for $7.95M Genprex Selects U.S. CDMO to Scale Diabetes Gene Therapy Manufacturing Symbiotec Pharmalab to Launch Rs 1,757 Crore($184M) IPO on August 24 Syneos Health Partners With Causaly to Embed Agentic AI Across Scientific CRO Workflows Gland Pharma Appoints Deepak Sapra as New CEO WuXi XDC Achieves GMP Release for Singapore Bioconjugate Production Line Medipost Signs CDMO Deal with QCellS for hiPSC Cell-Culture Media Lonza Introduces Rapid Media Service for Biopharma Development US Pharma Reshoring: The Full Policy Timeline CDMO Relationship Management Across the Americas: Why Culture Changes Everything Clinilabs Appoints IQVIA Veteran Laura Shannon as CEO to Lead CNS CRO Into Next Growth Phase BioCytics and LIDE Biotech Form CRO Alliance to Develop PDX Screening Platforms for Immuno-Oncology Cell Therapy Blue Jet Healthcare Opens New R&D Centre in Hyderabad PODCAST INTERVIEWS How to Connect a CDMO Network Without Starting From Scratch CDMO Relationship Management Across the Americas: Why Culture Changes Everything How To Complete a Dual-Site Biologics Tech Transfer in 90 Days
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study of Gemini in Acute Kidney Injury
BioCytics and LIDE Biotech Form CRO Alliance to Develop PDX Screening Platforms for Immuno-Oncology Cell Therapy
